UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1146-15
Program Prior Authorization/Notification
Medication Harvoni® (ledipasvir/sofosbuvir)
P&T Approval Date 10/2014, 2/2015, 8/2015, 11/2015, 12/2016, 12/2017, 12/2018, 2/2019,
2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Harvoni® (ledipasvir/sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus
(HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor,
and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric
patients 3 years of age or older.
• Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
• Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin
• Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with
compensated cirrhosis, in combination with ribavirin.
2. Coverage Criteriaa:
A. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve Patients without Cirrhosis and have
a pre-treatment HCV RNA less than 6 million IU/mL:
1. Harvoni will be approved based on all of the following criteria:
a. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
b. Patient has a pre-treatment HCV RNA less than 6 million IU/mL
-AND-
c. Patient is without cirrhosis
-AND-
d. Patient is treatment naïve [patient has not experienced treatment failure (defined as viral
relapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon
+/- ribavirin based regimen with or without an HCV protease inhibitor (e.g., Incivek,
Olysio, Victrelis) or Sovaldi (sofosbuvir)]
-AND-
e. Patient is not receiving Harvoni in combination with another HCV direct acting
© 2025 UnitedHealthcare Services, Inc.
1
antiviral agent [e.g., Sovaldi (sofosbuvir)]
Authorization will be issued for 8 weeks.
B. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve Patients without Cirrhosis and have
a pre-treatment HCV RNA equal to or greater than 6 million IU/mL:
1. Harvoni will be approved based on all of the following criteria:
a. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
b. Patient has a pre-treatment HCV RNA equal to or greater than 6 million IU/mL
-AND-
c. Patient is without cirrhosis
-AND-
d. Patient is treatment naïve [patient has not experienced treatment failure (defined as viral
relapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon
+/- ribavirin based regimen with or without an HCV protease inhibitor (e.g., Incivek,
Olysio, Victrelis) or Sovaldi (sofosbuvir)]
-AND-
e. Patient is not receiving Harvoni in combination with another HCV direct acting
antiviral agent [e.g., Sovaldi (sofosbuvir)]
Authorization will be issued for 12 weeks.
C. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve Patients with Compensated
Cirrhosis:
1. Harvoni will be approved based on all of the following criteria:
a. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
b. Patient has compensated cirrhosis (e.g., Child-Pugh A)
-AND-
c. Patient is treatment naïve [patient has not experienced treatment failure (defined as viral
relapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon
© 2025 UnitedHealthcare Services, Inc.
2
+/- ribavirin based regimen with or without an HCV protease inhibitor (e.g., Incivek,
Olysio, Victrelis) or Sovaldi (sofosbuvir)]
-AND-
d. Patient is not receiving Harvoni in combination with another HCV direct acting
antiviral agent [e.g., Sovaldi (sofosbuvir)]
Authorization will be issued for 12 weeks.
D. Chronic Hepatitis C - Genotype 1 - Treatment-Experienced Patients without Cirrhosis:
1. Harvoni will be approved based on all of the following criteria:
a. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
b. Patient has experienced failure with a previous treatment regimen of a peginterferon
alfa +/- ribavirin based regimen with or without an HCV protease inhibitor (e.g.,
Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)
-AND-
c. Patient is without cirrhosis
-AND-
d. Patient is not receiving Harvoni in combination with another HCV direct acting
antiviral agent [e.g., Sovaldi (sofosbuvir)]
Authorization will be issued for 12 weeks.
E. Chronic Hepatitis C - Genotype 1 - Treatment-Experienced Patients with Compensated
Cirrhosis:
1. Harvoni will be approved based on all of the following criteria:
a. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
b. Patient has experienced failure with a previous treatment regimen that included either
peginterferon alfa +/- ribavirin based regimen with or without an HCV protease
inhibitor (e.g., Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)
-AND-
© 2025 UnitedHealthcare Services, Inc.
3
c. Patient has compensated cirrhosis (e.g., Child-Pugh A)
-AND-
d. Patient is without decompensated liver disease (e.g., Child-Pugh B or C)
-AND-
e. One of the following:
(1) Patient will receive Harvoni in combination with ribavirin
-OR-
(2) Patient is not eligible for ribavirin
-AND-
f. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
In combination with ribavirin: Authorization will be issued for 12 weeks.
Ineligible for ribavirin: Authorization will be issued for 24 weeks.
F. Chronic Hepatitis C - Genotype 1 - Treatment-Naïve or Treatment-Experienced
Patients with Decompensated Cirrhosis:
1. Harvoni will be approved based on all of the following criteria:
a. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
b. Patient has decompensated liver disease (e.g., Child-Pugh B or C)
-AND-
c. Patient will receive Harvoni in combination with ribavirin
-AND-
d. Patient is not receiving Harvoni in combination with another HCV direct acting
antiviral agent [e.g., Sovaldi (sofosbuvir)]
Authorization will be issued for 12 weeks.
G. Chronic Hepatitis C - Genotype 4, 5 or 6 - Treatment-Naïve or Treatment-Experienced
© 2025 UnitedHealthcare Services, Inc.
4
Patients without Cirrhosis or with Compensated Cirrhosis:
1. Harvoni will be approved based on all of the following criteria:
a. Diagnosis of chronic hepatitis C genotype 4, 5 or 6 infection
-AND-
b. One of the following:
(1) Patient is without cirrhosis
-OR-
(2) Both of the following:
(a) Patient has compensated cirrhosis (e.g., Child-Pugh A)
-AND-
(b) Patient is without decompensated liver disease (e.g., Child-Pugh B or C)
-AND-
c. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
Authorization will be issued for 12 weeks.
H. Chronic Hepatitis C - Genotype 1 or 4 - Treatment-Naïve or Treatment-Experienced Liver
Transplant Recipients without Cirrhosis or with Compensated Cirrhosis:
1. Harvoni will be approved based on all of the following criteria:
a. Diagnosis of chronic hepatitis C genotype 1 or 4 infection
-AND-
b. Patient has previously received a liver transplant
-AND-
c. One of the following:
(1) Patient is without cirrhosis
-OR-
© 2025 UnitedHealthcare Services, Inc.
5
(2) Both of the following:
(a) Patient has compensated cirrhosis (e.g., Child-Pugh A)
-AND-
(b) Patient is without decompensated liver disease (e.g., Child-Pugh B or C)
-AND-
d. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
-AND-
e. Patient will receive Harvoni in combination with ribavirin
Authorization will be issued for 12 weeks.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• Medical necessity may be in place.
4. References:
1. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.
2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of
America. Recommendations for Testing, Managing, and Treating Hepatitis C.
http://www.hcvguidelines.org/full-report-view. Accessed December 19, 2024.
Program Prior Authorization/Notification - Harvoni™ (ledipasvir/sofosbuvir)
Change Control
10/2014 New program.
10/2014 Separated criteria sections to address treatment-naïve patients without
cirrhosis and pre-treatment HCV RNA equal to or greater than 6 million
IU/mL from the treatment-naïve patients with cirrhosis separately.
2/2015 Added Sovaldi as part of prior treatment criterion. Added criterion to
prevent combination therapy.
8/2015 Added criteria for genotype 4 infection.
11/2015 Added genotype 5 and 6 based updated FDA approval.
© 2025 UnitedHealthcare Services, Inc.
6
12/2016 Added criteria for genotype 1 patients with decompensated cirrhosis.
Updated genotype 1 treatment experienced criteria to include compensated
cirrhosis only. Added criteria for post liver transplant genotype 1 or 4
patients per updated FDA label. Updated references.
12/2017 Annual review with no change to clinical coverage criteria. Updated
references.
12/2018 Annual review with no change to clinical coverage criteria. Updated
references.
2/2019 Updated references and removed Olysio from examples.
2/2020 Annual review. Added additional background information. Updated
genotype 1 treatment-naïve criteria to include compensated cirrhosis only.
Updated genotype 1 treatment experienced criteria treatment regimen and
duration. Updated references.
2/2021 Annual review. Removed Olysio from list of examples for HCV direct
acting antiviral agent with no change to clinical intent. Updated references
2/2022 Annual review with no changes to coverage criteria. Updated references.
2/2023 Annual review. Revised coverage criteria for Genotype 1 treatment-
experienced patients with compensated cirrhosis per FDA label. Added
state mandate and updated references.
2/2024 Annual review. Added cirrhosis criteria for treatment of chronic hepatitis C
- genotype 4, 5 or 6.
2/2025 Annual review with no changes to coverage criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
7